newsfilter
← Latest News
GlobeNewswire·

ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF

Fremont, C, June 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology,